Background-We investigated the potential of conversion to sirolimus (SRL) as a primary immunosuppressant in attenuating cardiac allograft vasculopathy progression. Methods and Results-Twenty-nine cardiac transplant recipients were converted to SRL 3.8Ϯ3.4 years after transplantation with complete calcineurin inhibitor (CNI) withdrawal. Secondary immunosuppressants (azathioprine or mycophenolate) and steroids remained unchanged. Forty patients (controls) 4.8Ϯ4.0 years from transplantation were maintained on CNIs. Three-dimensional intravascular ultrasound studies were performed at baseline and 12.1Ϯ2.6 months later. 
C ardiac allograft vasculopathy (CAV), a complex multifactorial process arising from immune and nonimmune pathogenic mechanisms, 1 is the leading cause of late morbidity and mortality in heart transplant patients. The International Society of Heart and Lung Transplantation (ISHLT) registry in 2006 indicated that 5 years after cardiac transplantation, CAV and late graft failure (likely caused by CAV) together account for 30% of deaths. 2 CAV affects the microcirculation and large epicardial vessels, which results in progressive luminal narrowing 3 and reduced myocardial blood flow. 4 
Editorial p 2666 Clinical Perspective p 2733
The approach to CAV has been modification of underlying traditional risk factors and optimization of immunosuppression. Administration of lipid-lowering medications slows the development of CAV 5 and improves endothelial dysfunction. 6 Advances in immunosuppressive regimens in the past decade have improved short-term survival after heart transplantation but do not prevent CAV altogether.
Sirolimus (SRL) and derivatives (everolimus) are macrolide antibiotics with antiproliferative and potent antirejection properties. 7, 8 SRL blocks proliferative responses by inhibiting T-and B-cell responses to growth factors, a different pathway than calcineurin inhibitors (CNIs) 8 such as cyclosporin A or tacrolimus (FK506). In cardiac transplant recipients, SRL or its derivative everolimus has generally been used as a secondary immunosuppressive agent in place of azathioprine (AZA) or mycophenolate mofetil (MMF). 9 -11 SRL has been used infrequently as a primary immunosuppressant in cardiac transplant recipients. 12 We have previously reported that SRL is not nephrotoxic and may be used safely as primary immunosuppression in cardiac allograft recipients 13 to preserve renal function, leaving secondary immunosuppressive agents unchanged. However, no studies have yet demon-strated a beneficial effect on CAV progression when CNIs are replaced with SRL as primary immunosuppression. We hypothesized that replacement of CNIs with SRL would inhibit CAV progression. The aim of this study was to investigate the efficacy of SRL as primary immunosuppressant in preventing CAV progression as assessed by serial 3-dimensional (3D) intravascular ultrasound (IVUS) examination in a cohort of heart transplant patients.
Methods

Study Design
This was a nonrandomized, single-center study approved by the Mayo Clinic institutional review board. Since 2004, 3D IVUS has been performed on all cardiac transplant recipients, unless otherwise contraindicated, during routine annual coronary angiography as part of the surveillance for CAV. From January 2004 to July 2006, a total of 78 cardiac transplant recipients with impaired renal function secondary to CNI (defined as a corrected glomerular filtration rate [GFR] Յ50 mL/min and lack of any other identifiable causes of renal dysfunction) and/or CAV (any stenosis Ն50% in any major branch and/or distal pruning of secondary side branches) detected on annual coronary angiography were converted to SRL-based immunosuppression. Twenty-nine of these patients who had undergone 2 consecutive 3D IVUS exams were included (SRL group) in the study. Immunosuppression from CNI was changed to SRL as previously described 13 3.81Ϯ3.4 years (meanϮSD) after cardiac transplantation. Secondary immunosuppressive agents, MMF or AZA, were left unchanged, as was the existing dose of prednisone. A group of 40 cardiac transplant patients who were maintained on standard primary immunosuppression with cyclosporin A (Gengraf, Abbott Laboratories, Abbott Park, Ill; nϭ20) or FK506 (Prograf, Fujisawa Healthcare, Inc, Deerfield, Ill; nϭ20) and had undergone 2 consecutive IVUS exams in the same time frame were identified (CNI group) 4.80Ϯ4.0 years from transplant and comprise the control group. These patients were not formally matched to the SRL group.
Trough levels of immunosuppressants (cyclosporin A, FK506, and SRL) were measured through the use of high-performance liquid chromatography with tandem mass spectroscopy (API 4000, Applied Biosystems, Foster City, Calif). Therapeutic levels were 100 to 150 ng/mL for cyclosporin A, 6 to 8 ng/mL for FK506, and 10 to 15 ng/mL for SRL.
IVUS Examination and Analysis
IVUS was performed at baseline (before conversion to SRL in the SRL group and at the time of study entry in the CNI group) and at a 12-month follow-up. In 23 patients, baseline IVUS examinations were performed 0.62Ϯ0.64 years after transplantation ("early" group included patients who were enrolled in the study within first 2 years after transplantation). Another 46 patients were examined 6.29Ϯ3.25 years after transplantation ("late" group included patients enrolled in the study after 2 years after transplantation).
The methods for conducting IVUS have been described elsewhere. 14 Briefly, IVUS was performed during routine coronary angiography after intracoronary administration of 100 to 200 g nitroglycerin. Mechanical pullback (0.5 mm/s) was performed from the mid to distal left anterior descending coronary artery to the left main coronary artery with a 20-MHz, 2.9F, monorail, electronic Eagle Eye Gold IVUS imaging catheter (Volcano Therapeutics Inc, Rancho Cordova, Calif) and a dedicated IVUS scanner (Volcano Therapeutics). The IVUS images were stored on a CD-ROM for later offline 3D volumetric IVUS analysis.
Offline volumetric analysis of IVUS data was performed (echo Plaque 2, version 2.5, INDECSystems Inc, Santa Clara, Calif) by 2 experienced operators who were unaware of treatment assignment. The Simpson rule for volumetric measurement was used. Proximal and mid left anterior descending coronary artery coronary artery regions were defined for the interrogated artery. Starting with the first complete vascular ring distal to the bifurcation with the left circumflex artery lumen, plaque and vessel volume were analyzed. Each measured volume was normalized to the examined segment length (mm 3 /mm) to compensate for differences in examined vessel segment length. A plaque index (PI) was calculated as follows: (PV/vessel volume)ϫ100%, where PV is plaque volume. Changes in PV, lumen volume, and vessel volume or PI were defined as follow-up minus baseline volume measures value. The semiautomated contour detection of both the lumen and the media-adventitia interface was performed at intervals of either 16 or 32 frames, depending on the heterogeneity of the image. All other measurements were carried out automatically. Border detection was corrected manually in all frames after automatic border detection. Next, the vessel volume, lumen volume, and PV (mm 3 ) in the exact examined vessel segment length and frames were obtained and calculated as previously described. 15 
Statistical Analysis
Data were summarized through the use of meanϮSD (range) for numeric variables and percents and counts for categorical variables. Baseline characteristics between the SRL and CNI groups were compared by use of a t test for numerical data and a 2 test for categorical data. Differences from baseline to the 12-month follow-up within groups were compared by use of a paired t test. IVUS values at 12 months between groups were compared by ANCOVA, with the baseline value of the term included in the analysis as a covariate. Multivariable regression was used to assess independent predictors of plaque progression. A value of PϽ0.05 was considered statistically significant.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written. Table 1 provides baseline demographic and clinical characteristics on both groups of patients. The incidence of previous rejections was higher in the SRL group. Other baseline variables were not significantly different between the 2 groups. Laboratory measurements are summarized in Table 2 . Higher baseline creatinine, lower baseline GFR, and higher baseline uric acid levels in the SRL group reflect the fact that many patients with renal dysfunction were switched to SRL for preservation of renal function, as previously described. 13 There was no significant difference in baseline lipids and glucose levels between the 2 groups.
Results
Patient Characteristics
Of the 69 patients studied, 97% were on lipid-lowering therapy with pravastatin, simvastatin, or atorvastatin at the start of the study, and changes in lipid values were serially monitored. In the SRL group, additional therapy with ezetimibe (10 mg) in 2 patients, fish oil (2 to 3 g/d) in 7 patients, and gemfibrozil (1200 mg/d) in 2 patients was implemented to control elevations in serum triglycerides.
Volumetric Changes in the SRL and CNI Groups
Volumetric data by 3D IVUS at baseline and 12.1Ϯ2.6 months are shown in Table 3 . At baseline, PV and PI were higher in the SRL group, although not statistically significant. Mean progression in PV was significantly smaller in the SRL group than in the CNI group (0.1Ϯ1.13 versus 1. 28Ϯ2.86 mm 3 /mm; Pϭ0.0041; Figure 1A ). (For all figures, data are expressed as box-and-whiskers plots. The centerline depicts the median; the box depicts the interquartile range; and whiskers extend from the box to the outermost data point that falls within 1.5 times the interquartile range of the box. Points beyond that are displayed individually. MeanϮSD information also is displayed below.) The progression in PI also was significantly lower in the SRL group (Ϫ0.1Ϯ8% versus 6Ϯ8%; Pϭ0.005; Figure 1B) . As assessed by PI, 52% of the SRL group and 18% of the CNI group showed no disease progression (Pϭ0.0025). There were no significant changes between the CNI and SRL groups in vessel volume (0.34Ϯ3.24 versus 0.92Ϯ4.67; Pϭ0.57). There was no association between changes in PV and PI and baseline creatinine (Pϭ0.16 and Pϭ0.43, respectively), GFR (Pϭ0.21 and Pϭ0.61, respectively), and uric acid level (Pϭ0.19 and Pϭ0.59, respectively) in univariate analysis.
Multivariate analysis was performed for all patients in both groups using the following terms: age at first IVUS, indication for transplantation, donor age, ischemic time, presence of hypertension and diabetes, and baseline value of PV. After adjustment for the other factors in the multivariate analysis, the differences in PV (Pϭ0.001) and PI (Pϭ0.009) remained highly significant between the SRL and CNI groups.
Early and Late Plaque Volume Changes After Cardiac Transplantation
In patients studied within the first 2 years (early) after transplantation (mean, 8.5Ϯ7.2 months for the SRL group and 6.1Ϯ8.3 months for the CNI group), the progression in PV was markedly smaller in the SRL group than in the CNI group (0.06Ϯ1.06 versus 1.77Ϯ1.65 mm 3 /mm; Pϭ0.009; Figure 2A ). The progression in PI also was significantly smaller in the SRL group compared with the CNI group (0Ϯ9% in the SRL group versus 10Ϯ8% in the CNI group; Pϭ0.029; Figure 2B ). In patients observed beyond the first 2 years (late) after transplantation (5.6Ϯ3.1 years for the SRL group and 6.7Ϯ3.4 years for the CNI group), PV in the CNI group increased compared with the SRL group, but the difference was not statistically significant (0.13Ϯ1.20 versus 0.94Ϯ1.92 mm 3 /mm; Pϭ0.072; Figure 2A ). Similarly, PI progression was not statistically significant (0Ϯ6% for the SRL group versus 5Ϯ8% for the CNI group; Pϭ0.062; Figure 2B ). There were no changes between the CNI and SRL groups in vessel volume (0.78Ϯ3.70 mm 3 /mm in the CNI group versus 0.69Ϯ4.88 mm 3 /mm in the SRL group; Pϭ0.98). Figure 3A ). Patients treated with CNI/MMF, however, demonstrated a nonsignificant increase in PV compared with the SRL/MMF group (1.06Ϯ2.28 versus 0.05Ϯ1.45 mm 3 /mm; Pϭ0.085); there was no significant progression in PV compared with the SRL/AZA group (1.06Ϯ2.28 versus 0.22Ϯ0.66 mm 3 /mm; Pϭ0.14; Figure 3A ). Treatment with either AZA or MMF as a secondary immunosuppressant did not significantly affect changes in PI in either the SRL group (1.5Ϯ6% versus Ϫ1.6Ϯ8.5%; Pϭ0.14) or the CNI group (7.8Ϯ8.7% versus 4.8Ϯ7.3%; Pϭ0.23; Figure 3B ). Patients treated with CNI/MMF demonstrated a significantly increased PI compared with patients treated with SRL/MMF (4.8Ϯ7.3% versus Ϫ1.6Ϯ8.5%; Pϭ0.034) and no significant increase in PI compared with SRL/AZA patients (4.8Ϯ7.3% versus 1.5Ϯ6%; Pϭ0.36; Figure 3B ).
Secondary Immunosuppressive Agent Effects on PV and PI
Cardiac Function and Rejection
Cardiac function assessed by echocardiography remained normal in all patients. There were no coronary events and no significant changes in blood pressure or hypertensive management in both groups during the 12 months of follow-up. During the course of the study, 3 patients in the CNI group (7.5%) had 3 ISHLT 2004 grade 2R rejection episodes, and 2 patients in the SRL group (7%) had 3 ISHLT 2004 grade 2R rejection episodes (Pϭ0.92). All rejection episodes were detected on protocol biopsy and were treated with intravenous methylprednisolone. There was no hemodynamic compromise during rejections.
Laboratory Values
Laboratory characteristics are shown in Table 2 .
Lipids
In the SRL group, there was a significant increase in serum total cholesterol (187.1Ϯ39.2 mg/dL at baseline and 206.0Ϯ44.9 mg/dL on SRL; Pϭ0.02), with a significant increase in high-density lipoprotein cholesterol (56.2Ϯ17.7 mg/dL at baseline and 61.6Ϯ22.9 mg/dL on SRL; Pϭ0.04) and no changes in low-density lipoprotein cholesterol. There was a significant decrease in levels of cholesterol in the CNI group and a significant difference in total, low-density lipoprotein, and high-density lipoprotein cholesterol between SRL and CNI groups on follow-up (Table 2) .
Renal Function
Creatinine decreased significantly ( 
Uric Acid
There was a significant reduction in uric acid (7.4Ϯ1.9 versus 5.8Ϯ1.6 mg/dL; paired t test, Pϭ0.0001) in the SRL group and no change in uric acid levels (6.5Ϯ1.8 versus 6.4Ϯ1.7 mg/dL; paired t test, Pϭ0.75) in the CNI group.
Adverse Effects
Overall, SRL was well tolerated, and no patients were withdrawn from the study. Frequent side effects when SRL was initiated were gastrointestinal disturbance (nausea, diarrhea), greasy skin, and transient mouth ulcers. These symptoms usually resolved after 2 to 3 weeks.
Discussion
This is the first comparable serial 3D IVUS study that demonstrates the use of SRL as a primary immunosuppressive agent that mitigates the progression of CAV by reducing intimal hyperplasia. Moreover, our data indicate that a CNIfree regimen is safe and well tolerated and is most effective when initiated within the first 2 years after transplantation.
The diffuse nature of CAV limits the sensitivity of coronary angiography in long-term follow-up of this disease. 16 Therefore, IVUS is now considered the gold standard for the evaluation of CAV. 17 However, 2-dimensional IVUS has limitations in its sensitivity to detect the changes of atherosclerotic burden in CAV, difficulty with spatial registration, and an inability to assess the full extent of vascular disease. 18 We used 3D IVUS, which allows rapid and accurate measurement of volume and plaque dimensions that demonstrate the full extent of atherosclerotic pathology. Because of its superior reproducibility, this technique may be used to assess the progression of coronary artery disease and may allow more accurate evaluation of interventions aimed at preventing or retarding coronary artery disease. 14, 19 SRL has been shown to prevent vascular remodeling and neointimal proliferation, which are key components of CAV. 20 Although randomized clinical trials have evaluated the role of SRL or its derivative everolimus in combination with cyclosporine for the prevention of CAV, 10, 11 no study has examined the effect of complete CNI withdrawal and replacement with SRL on CAV progression. A recent multicenter, randomized, double-blind everolimus study showed that everolimus initiated 72 hours after transplantation in place of AZA was an effective adjunctive agent in reducing the incidence and severity of CAV at a 1-year follow-up. 10 SRL initiated immediately after transplantation as a secondary immunosuppressive agent in place of AZA also has been demonstrated to be effective in reducing acute allograft rejection and intimal thickening at a 2-year follow-up. 11 In a single-center, open-label randomized trial including patients with severe CAV, SRL as a secondary immunosuppressive agent in place of AZA also has been shown to lower the risk of subsequent coronary events and to slow the progression of existing CAV. 9 However, in these studies, questions have been raised regarding the greater increase in serum creatinine in the SRL or everolimus groups. 10, 11 This was most likely due to potentiation of the toxic effects of CNI that occur when SRL is introduced in the face of existing CNI therapy, likely because of increased CNI levels. 21 Although no wound healing issues were reported in the everolimus study, 10 in the multicenter SRL study, the trough levels of SRL were broad and high, which led to concerns about nephrotoxicity and wound healing, prompting a reduction in dose. 11 Similarly, in the study of Mancini et al, 9 concerns about delayed wound healing and renal dysfunction prompted a change in the therapeutic targets of SRL to lower levels than envisioned at the beginning of the study. In the present study, because all patients were converted to a CNI-free regimen, no exacerbation in renal dysfunction was seen.
In the present study, patients with CAV and significant renal dysfunction were converted to SRL. Therefore, the baseline renal function and plaque burden were worse in the SRL group and improved significantly during their follow-up visit the following year. Furthermore, on instituting the SRL regimen, we preemptively reduced the CNI dose, as previously described, to compensate for the possibility of nephrotoxicity. 13 Although the degree of proteinuria increased significantly in the SRL group, this increase was not associated with the development of nephrotic syndrome. Severe proteinuria has been seen in renal transplant recipients in whom it can be associated with nephrotic syndrome. 22 The antiproliferative effects are the likely mechanism for curtailing the progression of CAV in these patients. SRL attenuates endothelial cell proliferation and arterial smooth muscle cell proliferation and migration induced by plateletderived growth factor and basic fibroblast growth factor. 23, 24 In contrast, CNIs stimulates fibrogenic growth factor and transforming growth factor-␤ production, which may contribute to vasculopathy. 25 Recently, it has been shown that calcineurin pathways (negatively modulated by calsarcins) are critical in the remodeling of cardiac tissue when exposed to stress signals. 26 It is theoretically possible that prolonged use of CNIs may contribute to CAV via this mechanism in genetically predisposed cardiac transplant recipients.
It is possible that the same signals perpetuating intimal proliferation initiate a cascade of pathways that adversely affect the ability of the coronary vessel to positively remodel. Although intimal thickening traditionally has been the focus of research, several observations indicate that impaired positive remodeling also contributes to a net lumen loss. [27] [28] [29] Our study points out no difference in vessel volume between SRL-and CNI-treated patients despite significantly higher plaque burden in the CNI group; this suggests impaired positive remodeling in the CNI group compared with the SRL group.
Coronary endothelial dysfunction is an early characteristic feature of CAV. 30 CNIs have been shown to impair endothelial function through a number of mechanisms, including inhibition of nitric oxide synthase activity and a decrease in the level of endothelium-derived nitric oxide. 31, 32 In addition, cyclosporin A increases the production of thromboxane A 2 33 and inhibits local prostacyclin synthesis in vitro. 34 Cyclosporin A and its metabolites also increase the release of endothelin-1 from endothelial cells 35 and increase the expression of endothelin-1 receptors 36 in both human and animal kidney or renal cell cultures. CNIs also may contribute to CAV through other mechanisms, eg, hypertension with cyclosporin A use and diabetes with tacrolimus use. 37 Taken together, cumulating evidence suggests a therapeutic strategy that involves reducing the use of CNI, which may reduce the incidence of CAV. 38 Animal studies 39, 40 and a recent review of major immunosuppressive trials 41 have suggested that MMF may have a beneficial effect in attenuating the progression of CAV. In our study, the effect of the secondary immunosuppressant (MMF or AZA) was not significant, although patients treated with MMF preferentially had less intimal hyperplasia compared with the AZA treatment group (Figure 3A and 3B) .
We recognize that a main limitation of this study is that it is an observational open-label study and is neither blinded nor randomized. Although neither patient nor clinicians were blinded, 3D IVUS operators were unaware of which immunosuppressive agent the patients were taking. Higher incidence of previous rejections and worse baseline renal function in SRL-treated patients may have biased the sample. However, we were able to demonstrate significant mitigation of CAV progression even in this high-risk group of patients.
Another major limitation is that the results cannot be extrapolated to the implementation of SRL as a primary immunosuppressant in the early posttransplant period. We chose stable cardiac transplant recipients with no recent operative intervention because of concerns about SRL and wound healing. 42, 43 Therefore, further studies are needed to determine whether SRL is safe in the early posttransplant course. This is highlighted by the Heart Spare the Nephron (Heart-STN) trial, which was stopped prematurely and reported to the US Food and Drug Administration (http://www.fda.gov/ medwatch/safety/2007/cellcept DHCPletter 02-01-2007.pdf). However, this study proposed an abrupt switch from CNIbased immunosuppression at 3 months after cardiac transplantation without gradual CNI withdrawal, and questions were raised about the adequacy of SRL levels in patients who experienced rejection.
Conclusions
SRL not only is effective as a primary immunosuppressant compared with CNIs but also has antiproliferative properties that mitigate CAV progression by reducing intimal hyperplasia, as evidenced by serial 3D IVUS data in heart transplant recipients. Our findings suggest that SRL should be consid-ered as early as possible for primary immunosuppressive therapy after cardiac transplantation. This strategy has the potential to prevent or retard the development of CAV and to improve long-term survival after cardiac allotransplantation.
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